k-ras mutation, which leads to aberrant Ras/MAP-K pro-growth signalling, has been well studied in cancer (Cunningham and Weinberg, 1985; Nelson et al, 1999; Huber and Stratakis, 2004). The gene discussed is KRAS; the disease is cancer.